Portal de Periódicos da CAPES

Pharmacokinetics of Meropenem Determined by Microdialysis in the Peritoneal Fluid of Patients With Severe Peritonitis Associated With Septic Shock

2007; Wiley; Volume: 83; Issue: 3 Linguagem: Inglês

10.1038/sj.clpt.6100312

1532-6535

Juri Karjagin, Sandrine Lefeuvre, Kersti Oselin, Karin Kipper, Sandrine Marchand, A Tikkerberi, Joel Starkopf, William Couet, Sawchuk Rj,

Sepsis Diagnosis and Treatment

Clinical Pharmacology & TherapeuticsVolume 83, Issue 3 p. 452-459 Articles Pharmacokinetics of Meropenem Determined by Microdialysis in the Peritoneal Fluid of Patients With Severe Peritonitis Associated With Septic Shock J Karjagin, J Karjagin Clinic of Anaesthesiology and Intensive Care, University of Tartu, Tartu, EstoniaSearch for more papers by this authorS Lefeuvre, S Lefeuvre INSERM ERI-23 and University of Poitiers, Poitiers, France Laboratoire de Pharmacologie des Anti-infectieux, University of Poitiers, Poitiers, France Centre Hospitalier Universitaire de Poitiers, Poitiers, FranceSearch for more papers by this authorK Oselin, K Oselin Department of Pharmacology, University of Tartu, Tartu, EstoniaSearch for more papers by this authorK Kipper, K Kipper Department of Pharmacology, University of Tartu, Tartu, EstoniaSearch for more papers by this authorS Marchand, S Marchand INSERM ERI-23 and University of Poitiers, Poitiers, France Laboratoire de Pharmacologie des Anti-infectieux, University of Poitiers, Poitiers, France Centre Hospitalier Universitaire de Poitiers, Poitiers, FranceSearch for more papers by this authorA Tikkerberi, A Tikkerberi Clinic of Anaesthesiology and Intensive Care, University of Tartu, Tartu, EstoniaSearch for more papers by this authorJ Starkopf, J Starkopf Clinic of Anaesthesiology and Intensive Care, University of Tartu, Tartu, EstoniaSearch for more papers by this authorW Couet, W Couet INSERM ERI-23 and University of Poitiers, Poitiers, France Laboratoire de Pharmacologie des Anti-infectieux, University of Poitiers, Poitiers, France Centre Hospitalier Universitaire de Poitiers, Poitiers, FranceSearch for more papers by this authorRJ Sawchuk, Corresponding Author RJ Sawchuk [email protected] Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USASearch for more papers by this author J Karjagin, J Karjagin Clinic of Anaesthesiology and Intensive Care, University of Tartu, Tartu, EstoniaSearch for more papers by this authorS Lefeuvre, S Lefeuvre INSERM ERI-23 and University of Poitiers, Poitiers, France Laboratoire de Pharmacologie des Anti-infectieux, University of Poitiers, Poitiers, France Centre Hospitalier Universitaire de Poitiers, Poitiers, FranceSearch for more papers by this authorK Oselin, K Oselin Department of Pharmacology, University of Tartu, Tartu, EstoniaSearch for more papers by this authorK Kipper, K Kipper Department of Pharmacology, University of Tartu, Tartu, EstoniaSearch for more papers by this authorS Marchand, S Marchand INSERM ERI-23 and University of Poitiers, Poitiers, France Laboratoire de Pharmacologie des Anti-infectieux, University of Poitiers, Poitiers, France Centre Hospitalier Universitaire de Poitiers, Poitiers, FranceSearch for more papers by this authorA Tikkerberi, A Tikkerberi Clinic of Anaesthesiology and Intensive Care, University of Tartu, Tartu, EstoniaSearch for more papers by this authorJ Starkopf, J Starkopf Clinic of Anaesthesiology and Intensive Care, University of Tartu, Tartu, EstoniaSearch for more papers by this authorW Couet, W Couet INSERM ERI-23 and University of Poitiers, Poitiers, France Laboratoire de Pharmacologie des Anti-infectieux, University of Poitiers, Poitiers, France Centre Hospitalier Universitaire de Poitiers, Poitiers, FranceSearch for more papers by this authorRJ Sawchuk, Corresponding Author RJ Sawchuk [email protected] Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USASearch for more papers by this author First published: 08 August 2007 https://doi.org/10.1038/sj.clpt.6100312Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Our objective was to describe the pharmacokinetics of meropenem in the peritoneal fluid (PF) of six patients with severe peritonitis and septic shock and to relate measured concentrations to the minimum inhibitory concentration of bacteria. Microdialysis catheters were placed into the peritoneal space during surgery. Meropenem concentrations in plasma and in PF were analyzed using compartmental modeling. Meropenem areas under the concentration–time curve were lower in PF than in plasma (average ratio, 73.8±15%) because of degradation confirmed ex vivo. Compartment modeling with elimination from a peripheral compartment described the data adequately, and was used to simulate steady-state concentration profiles in plasma and PF during various dosing regimens. At the currently recommended dosing regimen of 1 g infused over 20 min every 8 h, PF concentrations of meropenem in patients with severe peritonitis associated with septic shock reach values sufficient for antibacterial effects against susceptible, but not always against intermediately susceptible, bacteria. Clinical Pharmacology & Therapeutics (2008) 83, 3,452–459.doi: 10.1038/sj.clpt.6100312 Citing Literature Volume83, Issue3PharmacoecologyMarch 2008Pages 452-459 RelatedInformation